Singapore markets close in 4 hours 5 minutes

AstraZeneca PLC (AZNCF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
146.20-12.30 (-7.76%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close158.50
Open153.90
Bid0.00 x 0
Ask0.00 x 0
Day's range146.20 - 154.20
52-week range118.16 - 159.84
Volume1,217
Avg. volume3,370
Market cap238.126B
Beta (5Y monthly)0.16
PE ratio (TTM)36.10
EPS (TTM)4.05
Earnings date25 Jul 2024
Forward dividend & yield2.86 (1.96%)
Ex-dividend date22 Feb 2024
1y target estN/A
  • Benzinga

    Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug

    Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi

  • Zacks

    AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

    AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

  • Benzinga

    Why Is AstraZeneca Stock Trading Lower On Tuesday?

    On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi